Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)

被引：5

作者：

Weickhardt, A. J. ^{[1
]}

Foroudi, F. ^{[2
]}

Xie, J. ^{[3
]}

Kanojia, K. ^{[3
]}

Sidhom, M. ^{[4
]}

Pal, A. ^{[5
]}

Grimison, P. ^{[6
]}

Zhang, A. ^{[7
]}

Ng, S. ^{[8
]}

Tang, C. ^{[9
]}

Hovey, E. ^{[10
]}

Chen, C. ^{[11
]}

Hruby, G. ^{[12
]}

Guminski, A. ^{[12
]}

Mcjannett, M. ^{[13
]}

Conduit, C. J. ^{[14
]}

Lawrentschuk, N. ^{[15
]}

Tran, B. ^{[16
]}

Davis, I. D. ^{[17
]}

Hayne, D. ^{[18
]}

机构：

[1] Olivia Newton John Canc Wellness & Res Ctr, Med Oncol, Heidelberg, Vic, Australia

[2] Olivia Newton John Canc Wellness & Res Ctr, Radiat Oncol, Heidelberg, Vic, Australia

[3] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia

[4] Liverpool Hosp, Radiat Oncol, South Western Sydney Local Hlth Dist, Liverpool, NSW, Australia

[5] Liverpool Hosp, Med Oncol, South Western Sydney Local Hlth Dist, Liverpool, NSW, Australia

[6] Chris Obrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia

[7] Chris Obrien Lifehouse, Med Oncol, Camperdown, NSW, Australia

[8] Sir Charles Gairdner Hosp, Med Oncol, Nedlands, WA, Australia

[9] Sir Charles Gairdner Hosp, Radiat Oncol, Nedlands, WA, Australia

[10] Prince Wales Hosp, Med Oncol, Nelune Comprehens Canc Ctr, Randwick, NSW, Australia

[11] Prince Wales Hosp, Radiat Oncol, Nelune Comprehens Canc Ctr, Randwick, NSW, Australia

[12] Royal North Shore Hosp, Radiat Oncol, St Leonards, NSW, Australia

[13] ANZUP Canc Clin Trials, Clin Trials Res, Camperdown, NSW, Australia

[14] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia

[15] Peter MacCallum Canc Ctr, Urol, Melbourne, Vic, Australia

[16] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia

[17] Monash Univ, Med Oncol, Eastern Hlth Clin Sch, Box Hill, Vic, Australia

[18] Fiona Stanley Hosp, Urol, Murdoch, WA, Australia

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.1817

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1739P

引用

页码：S1332 / S1332

页数：1

共 50 条

[1] Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)
Weickhardt, Andrew James
Foroudi, Farshad
Lawrentschuk, Nathan
Galleta, Laura
Seegum, Amanda
Herschtal, Alan
Link, Emma
McJannett, Margaret Mary
Liow, Elizabeth Chien Hern
Grimison, Peter S.
Zhang, Alison Yan
Patanjali, Nitya
Ng, Siobhan
Goodwin, Robert
Tang, Colin
Chen, Colin
Hovey, Elizabeth J.
Hruby, George
Guminski, Alexander David
Davis, Ian D.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[2] Pembrolizumab and chemoradiotherapy for muscle invasive bladder cancer: The ANZUP 1502 PCR-MIB trial.
Weickhardt, Andrew James
Foroudi, Farshad
Sengupta, Shomik
Galletta, Laura
Herschtal, Alan
Grimison, Peter S.
Patanjali, Nitya
Ng, Siobhan
Tang, Colin
Goodwin, Robert
Hovey, Elizabeth J.
Jarvis, Tom
Chen, Colin
Sandhu, Shahneen Kaur
Tai, Keen Hun
Lawrentschuk, Nathan
Davis, Ian D.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[3] Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)
Weickhardt, Andrew
Foroudi, Farshad
Lawrentschuk, Nathan
Xie, Jing
Sidhom, Mark
Pal, Abhijit
Grimison, Peter
Zhang, Alison
Ng, Siobhan
Tang, Colin
Hovey, Elizabeth
Chen, Colin
Hruby, George
Guminski, Alexander
McJannett, Margaret
Conduit, Ciara
Tran, Ben
Davis, Ian D.
Hayne, Dickon
EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (03): : 469 - 477
[4] Pembrolizumab with ChemoRadiotherapy for Muscle Invasive Bladder Cancer: the ANZUP PCR-MIB trial
Weickhardt, A. J.
Foroudi, F.
Sengupta, S.
Grimison, P.
Patanjali, N.
Leslie, S.
Ng, S.
Tang, C.
Goodwin, R.
Hovey, E.
Jarvis, T.
Chen, C.
Herschtal, A.
Galletta, L.
Sandhu, S.
Tai, K-H.
Lawrentschuk, N.
Davis, I.
ANNALS OF ONCOLOGY, 2016, 27
[5] TUXEDO: a phase I/II trial of cetuximab with chemoradiotherapy in muscle-invasive bladder cancer
James, Nicholas D.
Liu, Wenyu
Pirrie, Sarah
Kaur, Baljit
Hendron, Carey
Ford, Daniel
Zarkar, Anjali
Viney, Richard
Southgate, Elizabeth
Desai, Amisha
Hussain, Syed A.
BJU INTERNATIONAL, 2023, 131 (01) : 63 - 72
[6] Phase II study of concurrent chemoradiotherapy (CCRth) for bladder preservation in the treatment of muscle invasive bladder cancer
El Taher, A. Mohamed
Mekawy, M.
Eid, S. Shehata
Mostafa, H. G. El Din
Aziz, A. M. Abdel
Kamel, Y. Mostafa
EJC SUPPLEMENTS, 2007, 5 (04): : 310 - 310
[7] A randomized phase 3 trial of pembrolizumab versus placebo in patients with muscle-invasive bladder cancer receiving concurrent chemoradiotherapy
Shore, Neal D.
James, Nicholas D.
Van der Heijden, Michiel Simon
Balar, Arjun Vasant
Fang, Xiao
Kapadia, Ekta
Michalski, Jeff M.
Shariat, Shahrokh F.
Weickhardt, Andrew James
CANCER RESEARCH, 2022, 82 (12)
[8] Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
Habra, Mouhammed Amir
Stephen, Bettzy
Campbell, Matthew
Hess, Kenneth
Tapia, Coya
Xu, Mingxuan
Ahnert, Jordi Rodon
Jimenez, Camilo
Lee, Jeffrey E.
Perrier, Nancy D.
Boraddus, Russell R.
Pant, Shubham
Subbiah, Vivek
Hong, David S.
Zarifa, Abdulrazzak
Fu, Siqing
Karp, Daniel D.
Meric-Bernstam, Funda
Naing, Aung
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)
[9] Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Chemoradiotherapy Versus Chemoradiotherapy Alone in Muscle-invasive Bladder Cancer: The MK-3475-992/KEYNOTE-992 Trial
Tissot, Gabrielle
Xylinas, Evanguelos
EUROPEAN UROLOGY FOCUS, 2023, 9 (02): : 227 - 228
[10] Phase I trial of hypofractionated radiotherapy and pembrolizumab in the treatment of muscle invasive/metastatic bladder cancer: Results of the PLUMMB trial.
Huddart, Robert A.
Hafeez, Shaista
Nuzzaci, Emilia
Jones, Kelly
Tree, Alison
Greenlay, Emily
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)

← 1 2 3 4 5 →